news
Novel chemotherapeutic pro-drug approved for FIH trial in the UK
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
List view / Grid view
head and neck squamous cell carcinoma (HNSCC)
news
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
news
EC approves two new regimens of Keytruda for HNSCC
The European Commission has given its approval to Keytruda to treat head and neck squamous cell carcinoma as a monotherapy or in combination with a chemotherapy.
news
AstraZeneca head and neck cancer trials resume as FDA lifts clinical hold
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The Phase III KESTREL trial has already re-opened for new patient enrolment at some clinical study sites and the EAGLE trial is expected to resume shortly....
news
FDA approves Merck’s head and neck cancer drug
8 August 2016 | By Merck
Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon…
news
Merck releases new data for Keytruda at ASCO
6 June 2016 | By Victoria White, Digital Content Producer
Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells...
news
FDA accepts sBLA for Keytruda in head and neck cancer
13 April 2016 | By Victoria White, Digital Content Producer
The sBLA is for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy...
news
First patient enrolled in Phase II trial of ImmunoPulse IL-12
17 June 2015 | By Victoria White
OncoSec has enrolled the first patient into a Phase II clinical trial of ImmunoPulse IL-12 in patients with squamous cell carcinoma of the head and neck...